NCT04879329 2026-04-21
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
14 trialsNCT06966453 2026-04-21
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
Phase 1/2 Recruiting
NCT06157892 2026-03-17
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06178159 2025-10-01
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06642545 2025-02-17
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06378242 2024-07-11
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
RemeGen Co., Ltd.
Phase 1/2 Recruiting
NCT06227156 2024-05-23
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06389006 2024-05-23
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT06221748 2024-04-03
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
Phase 2/3 Recruiting
NCT06155396 2024-02-28
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05302284 2023-12-18
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT06155383 2023-12-14
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 2 Recruiting
NCT05940896 2023-11-27
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
RemeGen Co., Ltd.
Phase 1 Recruiting